Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

PI3K alpha/delta inhibitor TQ-B3525

An orally available selective inhibitor of the alpha and delta isoforms of phosphatidylinositol 3-kinase (PI3-kinase subunit alpha/delta; PI3K-alpha/delta; PI3Kalpha/delta), with potential antineoplastic activity. Upon oral administration, PI3K alpha/delta inhibitor TQ-B3525 selectively targets, binds to, and inhibits PI3K alpha and delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-alpha/delta over-expressing tumor cells. PI3K-alpha/delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-alpha/delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:TQ B3525
Code name:TQ-B3525
TQB3525
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search